Novartis' psoriasis drug yields positive results in late-stage trial

07/9/2013 | Reuters

Novartis' secukinumab worked better than Amgen's Enbrel in clearing the skin of people with moderate to severe plaque-type psoriasis in a Phase III trial. Novartis plans to submit the drug for regulatory review by year-end.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX